Answers are grounded in this paper and cite their sources.
Background: Intestinal epithelial barrier dysfunction, a major consequence of inflammatory and oxidative stress, contributes to enteric disorder progression. Salvianolic acid B (SAB), a prominent water-soluble phenolic compound in Salvia miltiorrhiza, shows intestinal protective potential, but the underlying mechanisms remain unclear. Methods: This study investigated the protective effects of SAB on intestinal barrier function using a lipopolysaccharide (LPS)-challenged piglet model and LPS-stimulated IPEC-J2 cells. Results: SAB alleviated LPS-induced intestinal injury, evidenced by reduced plasma diamine oxidase and D-lactate levels, improved intestinal morphology, decreased pro-inflammatory cytokines, and enhanced antioxidant capacity. SAB also strengthened intestinal barrier integrity by increasing goblet cell number and mucin 2 levels and upregulating tight junction protein expression. Moreover, SAB restored epithelial proliferation–apoptosis balance and increased PI3K/AKT/mTOR phosphorylation. Molecular docking and molecular dynamics simulations predicted a stable SAB–PI3Kα/p110α interaction, whereas LY294002 treatment attenuated SAB-mediated restoration of epithelial renewal and barrier integrity in LPS-treated IPEC-J2 cells. SAB also altered the jejunal microbial composition, including higher relative abundance of Streptococcus and lower relative abundance of Escherichia-Shigella, together with increased jejunal acetate and lactate concentrations. Conclusions: SAB alleviates inflammation-associated intestinal barrier dysfunction by restoring epithelial proliferation–apoptosis balance and regulating the microbiota–metabolite profile.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: